Masitinib targets mast cells, which play a critical role in severe forms of SCD and its complications, including vaso-occlusive crises, acute chest syndrome, and pain
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
This distinction is testament to LHWRF's dedication to excellence, transparency, and impact in the realm of social responsibility
Most recently, Yuvraj was the Director of Operations, Business Development & Process Excellence at Zeon Lifesciences Ltd
The therapy -- Ryoncil (remestemcel-L-rknd) -- will be tested in adults with severe steroid-refractory acute graft-versus-host disease
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
Subscribe To Our Newsletter & Stay Updated
